FDA Clears Dexcom’s Stelo OTC Continuous Glucose Monitor for Non-Insulin Users Aged Two and Up

August 2, 2026

Prime Therapeutics – Portal USA

Overview

The FDA has granted over-the-counter (OTC) marketing authorization for Dexcom’s Stelo Glucose Biosensor System, expanding its use to non-insulin users aged two and older. This marks the first OTC CGM approval for children and signifies a major stride in making real-time glucose monitoring broadly accessible without a prescription. The decision will enable a wider population, including individuals with prediabetes or those focused on wellness, to proactively manage their glucose levels and understand the impact of lifestyle choices.

In Depth

Key Findings

The U.S. Food and Drug Administration (FDA) announced on July 23, 2026, the first-ever over-the-counter (OTC) marketing authorization for Dexcom’s Stelo Glucose Biosensor System, now approved for non-insulin users aged two years and older. This significant regulatory decision extends the accessibility of continuous glucose monitoring (CGM) technology to a broader population, moving beyond its previous adult-only OTC clearance.

Technical / Clinical Details

The Stelo system employs a small, disposable sensor inserted under the skin, which continuously measures glucose levels and transmits data wirelessly to a compatible smartphone application. Designed for individuals not using insulin, the device empowers users to observe their glucose trends and understand how factors like diet, exercise, and stress influence their blood sugar. The expansion to a pediatric population (2 years and older) who do not rely on insulin therapy opens avenues for early awareness and proactive management of metabolic health, potentially aiding in the prevention of type 2 diabetes and supporting general wellness goals. Unlike traditional finger-prick tests, Stelo provides a comprehensive, real-time view of glucose dynamics, offering valuable insights that can inform daily decisions.

Background & Context

Historically, CGM devices were primarily prescribed for intensive diabetes management in insulin-dependent patients. However, the growing prevalence of prediabetes and a greater public interest in personalized health and wellness have driven demand for more accessible, less invasive monitoring solutions. This OTC clearance for Stelo represents a pivotal shift, democratizing access to sophisticated biometric data. It positions CGM not just as a disease management tool but as a broader health and lifestyle optimization device. The competitive landscape for CGM is intensifying, with manufacturers striving to improve accuracy, user experience, and cost-effectiveness. The FDA’s action reflects a broader trend toward empowering consumers with digital health tools.

Strategic Significance & Outlook

The approval of Stelo for a younger, non-insulin-using demographic is expected to significantly accelerate CGM adoption rates, particularly among those keen on preventing metabolic disorders or enhancing athletic performance. For Dexcom, it solidifies its leadership in the expanding consumer health market. This move will likely spur further innovation in non-invasive or minimally invasive biosensors and integrated digital health platforms. The ability to collect long-term, real-world glucose data from a diverse population of non-insulin users could also yield valuable insights for public health research and the development of new diagnostic and preventive strategies worldwide.

Source: https://www.primetherapeutics.com/trending-topics-drug-approvals-july-2026

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.